Techniques in Vascular & Interventional Radiology
Volume 10, Issue 1 , Pages 47-57 , March 2007

Cryoablation for Liver Cancer

  • J. Louis Hinshaw, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: J. Louis Hinshaw, MD, University of Wisconsin Department of Radiology, E3/311 CSC, 600 Highland Ave., Madison, WI 53792.
    • ,
  • Fred T. Lee Jr, MD

References 

  1. Parkin D, Bray F, Ferlay J, et al. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer. 2001;94:153–156
  2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750
  3. Balsells J, Charco R, Lazaro JL, et al. Resection of hepatocellular carcinoma in patients with cirrhosis. Br J Surg. 1996;83:758–761
  4. Gouillat C, Manganas D, Saguier G, et al. Resection of hepatocellular carcinoma in cirrhotic patients: Longterm results of a prospective study. J Am Coll Surg. 1999;189:282–290
  5. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: Long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961–967
  6. Lencioni R, Crocetti L. A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma. Clin Liver Dis. 2005;9:301–314viii
  7. Lencioni R, Della Pina C, Bartolozzi C. Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma. Abdom Imaging. 2005;30:401–408
  8. Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005;5:795–804
  9. Fontana RJ, Hamidullah H, Nghiem H, et al. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: A safe and effective bridge to liver transplantation. Liver Transpl. 2002;8:1165–1174
  10. Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology. 2005;41:1130–1137
  11. Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: Long-term results and prognostic factors in a large single-institution series. Eur Radiol. 2007;17:684–692
  12. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54:1151–1156
  13. Raut CP, Izzo F, Marra P, et al. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005;12:616–628
  14. Lu MD, Kuang M, Liang LJ, et al. [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: A randomized clinical trial]. Zhonghua Yi Xue Za Zhi. 2006;86:801–805
  15. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321–328
  16. Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210:655–661
  17. Liu Z, Ahmed M, Weinstein Y, et al. Characterization of the RF ablation-induced ‘oven effect’: The importance of background tissue thermal conductivity on tissue heating. Int J Hyperthermia. 2006;22:327–342
  18. Gilbert JC, Onik GM, Hoddick WK, et al. Real time ultrasonic monitoring of hepatic cryosurgery. Cryobiology. 1985;22:319–330
  19. Onik G, Cooper C, Goldberg HI, et al. Ultrasonic characteristics of frozen liver. Cryobiology. 1984;21:321–328
  20. Onik G, Gilbert J, Hoddick W, et al. Sonographic monitoring of hepatic cryosurgery in an experimental animal model. AJR Am J Roentgenol. 1985;144:1043–1047
  21. Lee FT, Chosy SG, Littrup PJ, et al. CT-monitored percutaneous cryoablation in a pig liver model: Pilot study. Radiology. 1999;211:687–692
  22. Silverman SG, Sun MR, Tuncali K, et al. Three-dimensional assessment of MRI-guided percutaneous cryotherapy of liver metastases. AJR Am J Roentgenol. 2004;183:707–712
  23. Tacke J, Adam G, Haage P, et al. MR-guided percutaneous cryotherapy of the liver: In vivo evaluation with histologic correlation in an animal model. J Magn Reson Imaging. 2001;13:50–56
  24. Pease GR, Wong ST, Roos MS, et al. MR image-guided control of cryosurgery. J Magn Reson Imaging. 1995;5:753–760
  25. Weber SM, Lee FT, Warner TF, et al. Hepatic cryoablation: US monitoring of extent of necrosis in normal pig liver. Radiology. 1998;207:73–77
  26. Shock SA, Laeseke PF, Sampson LA, et al. Hepatic hemorrhage caused by percutaneous tumor ablation: Radiofrequency ablation versus cryoablation in a porcine model. Radiology. 2005;236:125–131
  27. Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg. 1999;23:109–113discussion 113-114
  28. Ng KK, Lam CM, Poon RT, et al. Comparison of systemic responses of radiofrequency ablation, cryotherapy, and surgical resection in a porcine liver model. Ann Surg Oncol. 2004;11:650–657
  29. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: A multicenter phase II study. BMC Cancer. 2007;7:91
  30. Aparicio J, Fernandez-Martos C, Vincent JM, et al. FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2005;5:263–267
  31. Pasetto LM, Jirillo A, Iadicicco G, et al. FOLFOX versus FOLFIRI: A comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res. 2005;25:563–576
  32. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg. 2007;11:1057–1077
  33. Wang H, Littrup PJ, Duan Y, et al. Thoracic masses treated with percutaneous cryotherapy: Initial experience with more than 200 procedures. Radiology. 2005;235:289–298
  34. Muller-Schweinitzer E. Arterial smooth muscle function after prolonged exposure to a medium containing dimethyl sulfoxide (Me2SO) and storage at −196 degrees C. Cryobiology. 1994;31:330–335
  35. Clarke DM, Robilotto AT, Rhee E, et al. Cryoablation of renal cancer: Variables involved in freezing-induced cell death. Technol Cancer Res Treat. 2007;6:69–79
  36. Woolley ML, Schulsinger DA, Durand DB, et al. Effect of freezing parameters (freeze cycle and thaw process) on tissue destruction after renal cryoablation. J Endourol. 2002;16:519–522
  37. Campbell SC, Krishnamurthi V, Chow G, et al. Renal cryosurgery: Experimental evaluation of treatment parameters. Urology. 1998;52:29–33discussion 33-34
  38. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998;37:171–186
  39. Cooper IS, Hirose T. Application of cryogenic surgery to resection of parenchymal organs. N Engl J Med. 1966;274:15–18
  40. Permpongkosol S, Sulman A, Solomon SB, et al. Percutaneous computerized tomography guided renal cryoablation using local anesthesia: Pain assessment. J Urol. 2006;176:915–918
  41. Allaf ME, Varkarakis IM, Bhayani SB, et al. Pain control requirements for percutaneous ablation of renal tumors: Cryoablation versus radiofrequency ablation–initial observations. Radiology. 2005;237:366–370
  42. Hinshaw JL, Laeseke PF, Winter TC, et al. Radiofrequency ablation of peripheral liver tumors: Intraperitoneal 5% dextrose in water decreases postprocedural pain. AJR Am J Roentgenol. 2006;186:S306–S310
  43. Laeseke PF, Sampson LA, Winter TC, et al. Use of dextrose 5% in water instead of saline to protect against inadvertent radiofrequency injuries. AJR Am J Roentgenol. 2005;184:1026–1027
  44. Xu KC, Niu LZ, He WB, et al. Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma. World J Gastroenterol. 2003;9:2686–2689
  45. Ross WB, Horton M, Bertolino P, et al. Cryotherapy of liver tumours: A practical guide. HPB Surg. 1995;8:167–173
  46. Crews KA, Kuhn JA, McCarty TM, et al. Cryosurgical ablation of hepatic tumors. Am J Surg. 1997;174:614–617discussion 617-618
  47. Yeh KA, Fortunato L, Hoffman JP, et al. Cryosurgical ablation of hepatic metastases from colorectal carcinomas. Am Surg. 1997;63:63–68
  48. Lehner SG, Gould JE, Saad WE, et al. Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol. 2005;185:1307–1309
  49. Bagia JS, Perera DS, Morris DL. Renal impairment in hepatic cryotherapy. Cryobiology. 1998;36:263–267
  50. Seifert JK, Stewart GJ, Hewitt PM, et al. Interleukin-6 and tumor necrosis factor-alpha levels following hepatic cryotherapy: Association with volume and duration of freezing. World J Surg. 1999;23:1019–1026
  51. Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: Complications encountered in a multicenter study. Radiology. 2003;226:441–451
  52. de Baere T, Risse O, Kuoch V, et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol. 2003;181:695–700
  53. Dodd GD, Napier D, Schoolfield JD, et al. Percutaneous radiofrequency ablation of hepatic tumors: Postablation syndrome. AJR Am J Roentgenol. 2005;185:51–57
  54. Dill-Macky MJ, Asch M, Burns P, et al. Radiofrequency ablation of hepatocellular carcinoma: Predicting success using contrast-enhanced sonography. AJR Am J Roentgenol. 2006;186:S287–S295
  55. Minami Y, Kudo M, Kawasaki T, et al. Treatment of hepatocellular carcinoma with percutaneous radiofrequency ablation: Usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonography. AJR Am J Roentgenol. 2004;183:153–156
  56. Meloni MF, Goldberg SN, Livraghi T, et al. Hepatocellular carcinoma treated with radiofrequency ablation: Comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. AJR Am J Roentgenol. 2001;177:375–380
  57. Cioni D, Lencioni R, Rossi S, et al. Radiofrequency thermal ablation of hepatocellular carcinoma: Using contrast-enhanced harmonic power doppler sonography to assess treatment outcome. AJR Am J Roentgenol. 2001;177:783–788
  58. Solbiati L, Goldberg SN, Ierace T, et al. Radio-frequency ablation of hepatic metastases: Postprocedural assessment with a US microbubble contrast agent–early experience. Radiology. 1999;211:643–649
  59. Tateishi R, Shiina S, Yoshida H, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology. 2006;44:1518–1527
  60. Veit P, Antoch G, Stergar H, et al. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: Initial results. Eur Radiol. 2006;16:80–87
  61. Dromain C, de Baere T, Elias D, et al. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology. 2002;223:255–262

PII: S1089-2516(07)00073-X

doi: 10.1053/j.tvir.2007.08.005

Techniques in Vascular & Interventional Radiology
Volume 10, Issue 1 , Pages 47-57 , March 2007

Article Tools

* Image Usage & Resolution